The Chronic Malignancies Working Party promotes and conduct educational activities and clinical investigations on the role of hematopoietic cell transplantation in chronic malignancies such as chronic leukaemias, myelodysplastic syndromes, myeloproliferative and plasma cell disorders.
The CMWP aims to contribute to improving outcomes for patients undergoing stem cell transplantation for chronic hematologic malignancies by the following means:
- Performing high quality retrospective registry studies
- Performing prospective clinical trials and non-interventional studies (NIS)
- Improving the quality of EBMT registry data
- Promoting scientific interaction by organising educational courses and scientific meetings
- Collaborating with national and international transplant- and disease-specific groups
- Disseminating knowledge to the transplant and non-transplant scientific communities, patient organisations and the lay public
Learn more about the CMWP
The CMWP consists of six subcommittees:
- Myelodysplastic syndromes (MDS) including Chronic Myelomonocytic Leukaemia (CMML)
- Plasma Cell Disease (PCD)
- Philadelphia-negative Myeloproliferative Neoplasms (Ph-neg MPN)
- Chronic Myeloid Leukaemia (CML)
- Chronic Lymphocytic Leukaemia (CLL)
- Practice Harmonisation and Guidelines (PH&G)
Each subcommittee will have a chair and one or two vice-chairs.
Vice-chairs should act as co-chairs and should be directly responsible for at least two studies. (Chairs of subcommittees should allocate at least two studies to each vice-chair)
The chair of the CMWP appoints the chairs and vice-chairs of subcommittees.
Subcommittee members who have served over four years on the board may be replaced to provide opportunities for other interested WP members.
It is a goal of the current chair to have the board reflect the international range of EBMT-affiliated centres.
Working Party membership is open to all physicians in EBMT-affiliated Transplant Centres.
Applicants from elsewhere are welcome to apply to join. The final decision will rest with the Chair of the Working Party. The secretary maintains the list of members.
If a member has not attended any meeting for two years, they will be deemed to have left the Working Party and will no longer receive group email communications from the Secretary.
The Chronic Malignancies Working Party (CMWP) of the EBMT would like to invite you to participate in three studies all focused on allogeneic hematopoietic stem cell transplantation (alloSCT) for patients diagnosed with Chronic Lymphocyte Leukemia (CLL).
AlloSCT after Multiple Pathway Inhibitors:
We hypothesize that many nowadays transplanted patients for CLL have been pretreated with at least two pathway inhibitors (PI). The aim of this study is to describe the outcome of alloSCT of these patients in terms of PFS, OS, cumulative incidence of relapse (CIR) and NRM.
AlloSCT after stopping Ibrutinib for intolerance or relapse:
The aim of this study is to describe the outcome of alloSCT in CLL patients that were transplanted after Ibrutinib cessation in terms of PFS, OS, CIR and NRM.
Venetoclax before and after alloSCT for CLL:
Venetoclax is currently more and more widely used for relapsed CLL. Data on the use of Venetoclax before alloSCT or after alloSCT in the event of relapse or persistence of a detectable residual disease are lacking. The aim of this study is to describe the outcome of alloSCT in CLL patients that were transplanted after venetoclax use and/or treated with venetoclax after alloSCT in terms of PFS, OS, CIR and NRM and the response rate, PFS and OS in case venetoclax was given after alloSCT.
If your centre wishes to participate, please contact Nadia Erazo Castillo at firstname.lastname@example.org to receive the excel file with prefilled patient data.
The Chronic Malignancies Working Party (CMWP) of the EBMT would like to invite you to participate in a study called: “Post-Transplant Cyclophosphamide as GvHD Prophylaxis for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome as Compared to Standard GvHD Prophylaxis”.
The objective of the study is to evaluate the outcome of patients with MDS who underwent allogeneic HSCT and received GvHD prophylaxis with cyclophosphamide post-transplantation compared to those who received Antithymocyte Globulin (ATG). The primary endpoint of the study is GvHD-free/relapse free survival (GRFS).
Please note: to reduce the workload for your centre, we decided to randomly select a maximum of 15 ATG patients for inclusion.
If your centre wishes to participate, please contact Laurien Baaij at email@example.com to receive the excel file with prefilled patient data.